Cairo, M S
Tarek, N
Lee, D A
Delaney, C
Article History
Received: 24 February 2015
Revised: 1 July 2015
Accepted: 8 July 2015
First Online: 14 September 2015
Competing interests
: DAL has financial or ownership interest relating to <i>ex vivo</i> expansion of NK cells in Intrexon Corporation, Ziopharm Oncology and Cyto-Sen Therapeutics. The remaining authors declare no conflict of interest.